Intravenous steroid ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05154370 (ClinicalTrials.gov)	December 15, 2021	8/11/2021	China National Registry of CNS Inflammatory Demyelinating Diseases	China National Registry of Central Nervous System Inflammatory Demyelinating Diseases: a Prospective Cohort Study	Multiple Sclerosis;NMO Spectrum Disorder;Clinically Isolated Syndrome;CNS Demyelinating Autoimmune Diseases;Acute Disseminated Encephalomyelitis	Drug: Intravenous steroid	Beijing Tiantan Hospital	NULL	Recruiting	N/A	N/A	All	10000		China
2	NCT01411514 (ClinicalTrials.gov)	August 2011	26/5/2011	Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis	Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort	Multiple Sclerosis	Drug: Prednisone;Drug: Placebo	Claudio Gobbi	Ente Ospedaliero Cantonale, Ticino, Switzerland	Terminated	18 Years	80 Years	Both	27	Phase 4	Switzerland